The Prognosis of Patients After Coronary Intervention (PCI) : a Multi-center Prospective Study in China

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
View:

• Participants who understand and sign the informed consent voluntarily;

• Age ≥ 18 years old and ≤ 80 years old, regardless of sex;

• The hospitalized patients with coronary heart disease undergoing PCI;

• Complete all planned PCI during hospitalization.

Locations
Other Locations
China
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Miao Yu
yumiaodavid@126.com
+862785726009
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2027-11-01
Participants
Target number of participants: 2400
Sponsors
Leads: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Jingzhou Central Hospital, The First Affiliated Hospital of Xiamen University, Wuhan Asia Heart Hospital, Wuhan Fourth Hospital, The First Hospital of Wuhan, Wuhan Central Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, Shanxi Cardiovascular Hospital, The First Affiliated Hospital of Zhengzhou University, First People's Hospital of Xianyang, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, The First Affiliated Hospital of Anhui Medical University, Yichang Central People's Hospital, Fifth Hospital in Wuhan, Hubei University of Medicine, Shandong Provincial Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials